Cell viability monitoring kits are estimated at 41.0% of kit type demand in 2026 while quality control testing holds 39.0% and biopharmaceutical companies account for 45.0%. Adoption depends on assays that transfer between development and release workflows while method comparability and short product shelf life constrain qualification.